The YCC Administration provides infrastructure to promote cancer research activities of its 260 members, with a particular emphasis on facilitating transdisciplinary and translational research. The Administration supports the Director, Senior Leaders, Program Leaders, Shared Resources Directors and YCC Members in carrying out the YCC mission through effective management, centralized resources, and strategic planning. YCC Administrative responsibilities: ? Communicate between and among Center Director, Deputy, Associate and Assistant Directors,, Program Leaders, Shared Resource Directors and stakeholders within and outside the Institution; ? Develop and implement the YCC strategic plan in concert with the Center's leadership and integrate recommendations from standing and ad hoc advisory boards; ? Develop and coordinate research administration activities to support planning and evaluation, integrate and promote the collaborative, transdisciplinary and translational research activities of the YCC; ? Provide financial management of all YCC and CCSG funds and accounts;maintain fiduciary responsibility including preparing and maintaining annual operating,, capital and Shared Resource budgets;intra- and extramural research fund management;tracking Shared Resource usage;preparing grants, contracts and other financial reports; * Provide personnel and human resource services in support of YCC leadership and membership; * Manage Shared-Resources and provide financial oversight, data on usage patterns, and determine chargeback rate; * Manage YCC facilities, space, and equipment; * Manage and coordinate funding opportunities including intramural pilot project programs and other research project post award management; * Support and coordinate YCC membership application and review processes; * Manage and respond to research information technology and informatics needs; * Coordinate YCC committees;management of human resources, development, marketing, public affairs, and education programs.
The administration is a key component of the YCC. A highly effective administration is of paramount importance for the YCC and its members to achieve their missions. The administration's chief priority is to ensure the effective execution of business, administrative, and financial operations such that the research activities of YCC members can flourish.
|Yanez, Diana A; Lacher, Richard K; Vidyarthi, Aurobind et al. (2017) The role of macrophages in skin homeostasis. Pflugers Arch 469:455-463|
|Langdon, Casey G; Platt, James T; Means, Robert E et al. (2017) Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Mol Cancer Ther 16:1041-1053|
|Kim, Bong-Sung; Ott, Veronica; Boecker, Arne Hendrick et al. (2017) The Effect of Antiseptics on Adipose-Derived Stem Cells. Plast Reconstr Surg 139:625-637|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2017) Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res :|
|Toki, Maria I; Cecchi, Fabiola; Hembrough, Todd et al. (2017) Proof of the quantitative potential of immunofluorescence by mass spectrometry. Lab Invest 97:329-334|
|Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192|
|Wang, Simeng; Yang, Xiaoyong (2017) Inter-organ regulation of adipose tissue browning. Cell Mol Life Sci 74:1765-1776|
|Acharya, Dhiraj; Wang, Penghua; Paul, Amber M et al. (2017) Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance. J Virol 91:|
|Swartz, Kelsey L; Wood, Scott N; Murthy, Tushar et al. (2017) E2F-2 Promotes Nuclear Condensation and Enucleation of Terminally Differentiated Erythroblasts. Mol Cell Biol 37:|
|Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania et al. (2017) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecol Oncol 146:179-186|
Showing the most recent 10 out of 631 publications